Oligodendroglioma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) No edit summary |
|||
| (22 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Oligodendroglioma}} | {{Oligodendroglioma}} | ||
{{CMG}}{{AE}}{{SR}} | {{CMG}}{{AE}}{{S.M.}}{{SR}} | ||
==Overview== | ==Overview== | ||
Some [[patients]] with [[oligodendroglioma]] may have elevated [[protein]] and [[cell]] count with normal [[glucose]] and [[lactate]] on [[Lumbar puncture|CSF analysis]], which is usually [[Suggestion|suggestive]] of [[hydrocephalus]]. [[Immunohistochemistry]] of [[oligodendrogliomas]] shows positive [[staining]] for [[Isocitrate dehydrogenase|IDH1-R132H]], [[ATRX]], [[GFAP]], [[SOX10]], [[Microtubule-associated protein|MAP2]], [[S100 calcium binding protein A8|S-100]], EMA, [[Ki-67 (Biology)|Ki-67]], [[Neuron-Specific Enolase (NSE)|NSE]], [[synaptophysin]], [[OLIG1|OLIG1,]] and [[OLIG2]], and [[Negative-sense|negative]][[staining]] for [[p53]], and [[keratins]]. | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
===Lumbar Puncture=== | ===Lumbar Puncture=== | ||
*Some patients with oligodendroglioma may have elevated [[protein]] and cell count with normal [[glucose]] and [[lactate]] on [[lumbar puncture|CSF analysis]], which is usually suggestive of [[hydrocephalus]] | *Some [[patients]] with [[oligodendroglioma]] may have elevated [[protein]] and [[cell]] count with normal [[glucose]] and [[lactate]] on [[lumbar puncture|CSF analysis]], which is usually [[Suggestion|suggestive]] of [[hydrocephalus|hydrocephalus.]]<ref name="pmid20052406">{{cite journal| author=Stark AM, Hugo HH, Mehdorn HM, Knerlich-Lukoschus F| title=Acute Hydrocephalus due to Secondary Leptomeningeal Dissemination of an Anaplastic Oligodendroglioma. | journal=Case Rep Med | year= 2009 | volume= 2009 | issue= | pages= 370901 | pmid=20052406 | doi=10.1155/2009/370901 | pmc=PMC2797365 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20052406 }} </ref><ref name="pmid16048288">{{cite journal| author=Li KW, Roonprapunt C, Lawson HC, Abbott IR, Wisoff J, Epstein F et al.| title=Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas. | journal=Neurosurg Focus | year= 2005 | volume= 18 | issue= 6A | pages= E2 | pmid=16048288 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16048288 }} </ref> | ||
*[[ | ===Immunohistochemical staining=== | ||
*[[Oligodendrogliomas]] [[Staining|stain]] positive for:<ref name="IHC">IHC of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma</ref><ref name="pmid16622556">{{cite journal| author=Hilbig A, Barbosa-Coutinho LM, Netto GC, Bleil CB, Toscani NV| title=[Immunohistochemistry in oligodendrogliomas]. | journal=Arq Neuropsiquiatr | year= 2006 | volume= 64 | issue= 1 | pages= 67-71 | pmid=16622556 | doi=/S0004-282X2006000100014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16622556 }} </ref><ref name="von DeimlingHartmann2005">{{cite journal|last1=von Deimling|first1=A|last2=Hartmann|first2=C|title=Oligodendrogliomas: Impact of molecular genetics on treatment|journal=Neurology India|volume=53|issue=2|year=2005|pages=140|issn=0028-3886|doi=10.4103/0028-3886.16394}}</ref><ref name="pmid26671986">{{cite journal| author=Tanboon J, Williams EA, Louis DN| title=The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. | journal=J Neuropathol Exp Neurol | year= 2016 | volume= 75 | issue= 1 | pages= 4-18 | pmid=26671986 | doi=10.1093/jnen/nlv009 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26671986 }} </ref><ref name="pmid25324168">{{cite journal| author=Kato Y| title=Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. | journal=Brain Tumor Pathol | year= 2015 | volume= 32 | issue= 1 | pages= 3-11 | pmid=25324168 | doi=10.1007/s10014-014-0202-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25324168 }} </ref> | |||
**[[Isocitrate dehydrogenase|IDH1-R132H]] (majority of cases) | |||
**[[ATRX]] | |||
**[[GFAP]] (positive in intermingled reactive [[astrocytes]] and minigemistocytes) | |||
**[[SOX10]] | |||
**[[Microtubule-associated protein|MAP2]] | |||
**[[S100 calcium binding protein A8|S-100]] | |||
**EMA | |||
**[[Ki-67 (Biology)|Ki-67]] | |||
**[[Neuron-Specific Enolase (NSE)|NSE]] | |||
**[[Synaptophysin]] | |||
**[[OLIG1]] | |||
**[[OLIG2]] | |||
*[[Oligodendrogliomas]] [[Staining|stain]] negative for: | |||
**[[p53]] ([[rare]] weakly positive [[Cells (biology)|cells]] can be seen) | |||
**[[Keratins]] (although cocktails may show cross reactivity) | |||
==References== | ==References== | ||
{{Reflist| | {{Reflist|1}} | ||
[[Category:Neurological disorders]] | [[Category:Neurological disorders]] | ||
| Line 17: | Line 34: | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 04:56, 5 June 2019
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma laboratory tests |
|
Risk calculators and risk factors for Oligodendroglioma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Some patients with oligodendroglioma may have elevated protein and cell count with normal glucose and lactate on CSF analysis, which is usually suggestive of hydrocephalus. Immunohistochemistry of oligodendrogliomas shows positive staining for IDH1-R132H, ATRX, GFAP, SOX10, MAP2, S-100, EMA, Ki-67, NSE, synaptophysin, OLIG1, and OLIG2, and negativestaining for p53, and keratins.
Laboratory Findings
Lumbar Puncture
- Some patients with oligodendroglioma may have elevated protein and cell count with normal glucose and lactate on CSF analysis, which is usually suggestive of hydrocephalus.[1][2]
Immunohistochemical staining
- Oligodendrogliomas stain positive for:[3][4][5][6][7]
- IDH1-R132H (majority of cases)
- ATRX
- GFAP (positive in intermingled reactive astrocytes and minigemistocytes)
- SOX10
- MAP2
- S-100
- EMA
- Ki-67
- NSE
- Synaptophysin
- OLIG1
- OLIG2
- Oligodendrogliomas stain negative for:
References
- ↑ Stark AM, Hugo HH, Mehdorn HM, Knerlich-Lukoschus F (2009). "Acute Hydrocephalus due to Secondary Leptomeningeal Dissemination of an Anaplastic Oligodendroglioma". Case Rep Med. 2009: 370901. doi:10.1155/2009/370901. PMC 2797365. PMID 20052406.
- ↑ Li KW, Roonprapunt C, Lawson HC, Abbott IR, Wisoff J, Epstein F; et al. (2005). "Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas". Neurosurg Focus. 18 (6A): E2. PMID 16048288.
- ↑ IHC of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma
- ↑ Hilbig A, Barbosa-Coutinho LM, Netto GC, Bleil CB, Toscani NV (2006). "[Immunohistochemistry in oligodendrogliomas]". Arq Neuropsiquiatr. 64 (1): 67–71. doi:/S0004-282X2006000100014 Check
|doi=value (help). PMID 16622556. - ↑ von Deimling, A; Hartmann, C (2005). "Oligodendrogliomas: Impact of molecular genetics on treatment". Neurology India. 53 (2): 140. doi:10.4103/0028-3886.16394. ISSN 0028-3886.
- ↑ Tanboon J, Williams EA, Louis DN (2016). "The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas". J Neuropathol Exp Neurol. 75 (1): 4–18. doi:10.1093/jnen/nlv009. PMID 26671986.
- ↑ Kato Y (2015). "Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas". Brain Tumor Pathol. 32 (1): 3–11. doi:10.1007/s10014-014-0202-4. PMID 25324168.